Literature DB >> 7699056

Effect of delayed specimen processing on cytomegalovirus antigenemia test results.

M L Landry1, D Ferguson, S Cohen, K Huber, P Wetherill.   

Abstract

Blood samples held at either 4 degrees C or room temperature for 1 day had similar mean decreases in number of cytomegalovirus antigenemia-positive cells (52 to 55%) and similar false-negative test results (13 to 14%). After 2 days, samples held at 4 degrees C showed no further decline, whereas samples held at room temperature had a mean 81% decrease in positive cells, a 32% false-negative rate, and a more marked deterioration in cell morphology.

Mesh:

Substances:

Year:  1995        PMID: 7699056      PMCID: PMC227925          DOI: 10.1128/jcm.33.1.257-259.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Cytomegalovirus antigenemia assay.

Authors:  M van der Giessen; T H The; W J van Son
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

2.  Prospective study of cytomegalovirus antigenemia in allograft recipients.

Authors:  H Miller; E Rossier; R Milk; C Thomas
Journal:  J Clin Microbiol       Date:  1991-05       Impact factor: 5.948

Review 3.  Cytomegalovirus antigenemia.

Authors:  T H The; W van der Bij; A P van den Berg; M van der Giessen; J Weits; H G Sprenger; W J van Son
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

4.  The effect of various cell separation procedures on assays of neutrophil function. A critical appraisal.

Authors:  L Glasser; R L Fiederlein
Journal:  Am J Clin Pathol       Date:  1990-05       Impact factor: 2.493

5.  Factors influencing detection of quantitative cytomegalovirus antigenemia.

Authors:  M Boeckh; P M Woogerd; T Stevens-Ayers; C G Ray; R A Bowden
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

6.  Effect of delayed processing of blood samples on performance of cytomegalovirus antigenemia assay.

Authors:  J Niubò; J L Pérez; A Carvajal; C Ardanuy; R Martín
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

7.  Effects of temperature on granulocyte preservation.

Authors:  J McCullough; B J Wieblen; P K Peterson; P G Quie
Journal:  Blood       Date:  1978-08       Impact factor: 22.113

8.  Comparison of quantitative cytomegalovirus antigenemia assay with culture methods and correlation with clinical disease.

Authors:  M L Landry; D Ferguson
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

9.  Comparison between viremia and antigenemia for detection of cytomegalovirus in blood.

Authors:  W van der Bij; J Schirm; R Torensma; W J van Son; A M Tegzess; T H The
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

10.  Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia.

Authors:  G Gerna; M G Revello; E Percivalle; F Morini
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

  10 in total
  15 in total

1.  Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation.

Authors:  C Aitken; W Barrett-Muir; C Millar; K Templeton; J Thomas; F Sheridan; D Jeffries; M Yaqoob; J Breuer
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation.

Authors:  A Weinberg; T N Hodges; S Li; G Cai; M R Zamora
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenemia test kits, biotest CMV brite and Bartels/Argene CMV antigenemia.

Authors:  K St George; M J Boyd; S M Lipson; D Ferguson; G F Cartmell; L H Falk; C R Rinaldo; M L Landry
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

4.  Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation.

Authors:  Xiaoli L Pang; Linda Chui; Jayne Fenton; Barbara LeBlanc; Jutta K Preiksaitis
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects.

Authors:  G Boivin; J Handfield; E Toma; G Murray; R Lalonde; V J Tevere; R Sun; M G Bergeron
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

6.  Evaluation of a leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay.

Authors:  C E Bush; J A Sluchak-Carlsen
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

7.  Evaluation of CMV Brite kit for detection of cytomegalovirus pp65 antigenemia in peripheral blood leukocytes by immunofluorescence.

Authors:  M L Landry; D Ferguson; T Stevens-Ayers; M W de Jonge; M Boeckh
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

8.  Comparison of culture and the antigenemia assay for detection of cytomegalovirus in blood specimens submitted to a reference laboratory.

Authors:  B G Brumback; S N Bolejack; M V Morris; C Mohla; T E Shutzbank
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

9.  Novel DNA assay for cytomegalovirus detection: comparison with conventional culture and pp65 antigenemia assay.

Authors:  N Veal; C Payan; D Fray; L Sarol; O Blanchet; S Kouyoumdjian; F Lunel
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

10.  Evaluation of the murex hybrid capture cytomegalovirus DNA assay versus plasma PCR and shell vial assay for diagnosis of human cytomegalovirus viremia in immunocompromised patients.

Authors:  W Y Barrett-Muir; C Aitken; K Templeton; M Raftery; S M Kelsey; J Breuer
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.